Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3927 dose optimization study in propionic acidemia
2022-502910-10-00Phase 2Authorised
- Sponsor
- Moderna Inc
- Start
- Jun 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 2, open-label trial of mRNA-3927 in propionic acidemia (PA) (3 arms), sponsored by Moderna Inc. Planned start Jun 2024; status: authorised.
02
Drugs
mRNA-3927
03
Conditions
propionic acidemia (PA)
Beyond the preview
Go deeper on 2022-502910-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502910-10-00.